GlassScriptPhysician profile
Brooke Jones
NPI 1821712522
$6,214.88
in general payments reported to CMS, 2019-2025
34 companies · $3,620 in 2025
The $3,620 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $588 · 2024: $2,007 · 2025: $3,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Travel and Lodging: $1,472 · Consulting Fee: $700 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.76 |
| Travel and Lodging | $1,472.22 |
| Consulting Fee | $700.00 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,023.05 | 2024-2025 | Bimzelx |
| Abbvie INC. | $814.59 | 2023-2025 | |
| Botanix Sb INC | $712.25 | 2025 | Sofdra |
| Novo Nordisk INC | $577.99 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $341.02 | 2024-2025 | Descovy |
| Astrazeneca Pharmaceuticals LP | $245.72 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $229.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $162.04 | 2025 | |
| Sonex Health, INC. | $150.76 | 2024 | Sx-One Microknife |
| Otsuka America Pharmaceutical, INC. | $123.67 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $105.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $70.77 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.56 | 2024 | Caplyta |
| Leo Pharma INC. | $62.98 | 2025 | Anzupgo, Adbry |
| Janssen Pharmaceuticals, INC | $56.78 | 2024 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.72 | 2023 | Sotyktu |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.14 | 2024-2025 | Xifaxan |
| Viiv Healthcare Company | $33.31 | 2024 | Apretude |
| Lundbeck LLC | $32.80 | 2025 | Rexulti |
| Dexcom, INC. | $29.23 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $28.55 | 2025 | Auvelity |
| Corcept Therapeutics | $25.60 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $25.16 | 2023 | |
| Sanofi Pasteur INC. | $23.00 | 2023 | |
| Organon LLC | $21.85 | 2025 | Nexplanon |
| Abiomed | $20.57 | 2024 | Impella |
| Photonicare INC | $20.34 | 2025 | Otosight Middle Ear Scope |
| Nevro Corp. | $19.99 | 2024 | Senza |
| Glaxosmithkline, LLC. | $16.78 | 2024 | Shingrix, Arexvy, Bexsero |
| Sun Pharmaceutical Industries INC. | $15.85 | 2025 | |
| Currax Pharmaceuticals LLC | $15.68 | 2024 | Onzetra Xsail, Contrave |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2025 | Zoryve |
| Phadia US INC. | $15.18 | 2025 | Immunocap |
| Exeltis, USA INC. | $15.06 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.